DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Liraglutide 3.0 mg (Saxenda). Adults with overweight plus comorbidity, or obesity, without diabetes.
Percent change in body weight at week 56.
Mean weight loss 8.0% with liraglutide vs 2.6% with placebo. 63.2% lost ≥5% vs 27.1% placebo. First weight-loss GLP-1 to gain FDA approval.
Adults with overweight plus comorbidity, or obesity, without diabetes.
Daily subcutaneous liraglutide 3.0 mg vs placebo with lifestyle.
Percent change in body weight at week 56.
Mean weight loss 8.0% with liraglutide vs 2.6% with placebo. 63.2% lost ≥5% vs 27.1% placebo. First weight-loss GLP-1 to gain FDA approval.
Pi-Sunyer X et al, NEJM 2015;373:11-22